Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elafibranor - Ipsen

Next Previous
X
Search
Drug Profile

Elafibranor - Ipsen

Alternative Names: GFT-505; IPN-60190; IQIRVO; Iqirvo

Latest Information Update: 26 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genfit
  • Developer Genfit; Ipsen
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics; Hepatoprotectants; Organic sulfur compounds; Phenyl ethers; Propionic acids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Primary biliary cirrhosis
  • Phase II Primary sclerosing cholangitis
  • Discontinued Hepatic fibrosis; Lipid metabolism disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 26 Aug 2024 Pharmacokinetics and adverse events data from a drug-drug interaction phase I trial presented at the Digestive Disease Week, 2024 (DDW-2024)
  • 26 Jul 2024 Ipsen anticipates final decision on marketing authorization for elafibranor (Treatment-experienced, Monotherapy, Combination therapy) in the EU, in Q3 of 2024
  • 26 Jul 2024 Preregistration for Primary biliary cirrhosis (Treatment-experienced, Combination therapy) in European Union (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top